AlphaCentric Advisors’s Blueprint Medicines BPMC Stock Holding History

AlphaCentric Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-550	Closed	-$51K	–	208
2020 Q3	$51K	Buy	+550	New	+$42.4K	0.02%	105

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AlphaCentric Advisors's BPMC Position: Q4 2020 in Review

AlphaCentric Advisors sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 550 shares — an estimated $51K sold.

AlphaCentric Advisors first reported a position in BPMC in Q3 2020 and held it in 1 quarter. The position peaked at $51K in Q3 2020. 278 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

AlphaCentric Advisors reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
AlphaCentric Advisors sold 550 Blueprint Medicines shares in Q4 2020, an estimated $51K.
AlphaCentric Advisors first reported a position in Blueprint Medicines in Q3 2020 and held it in 1 quarter.
AlphaCentric Advisors's Blueprint Medicines position peaked at $51K in Q3 2020.
278 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on AlphaCentric Advisors's 13F filing for Q4 2020, filed 11 Mar 2022.